Plerixafor Accord

plerixafor

Overview
Authorisation details
Product information
Assessment history

Authorised

This medicine is authorised for use in the European Union.

Overview

Plerixafor Accord is a medicine used to mobilise blood stem cells from a patient’s bone marrow so that they can be collected and used later for transplantation in the same patient.

Plerixafor Accord is used together with the hormone granulocyte-colony stimulating factor (G-CSF) and is intended only for patients in whom collection of stem cells is difficult.

The patients who are given Plerixafor Accord are:

adults with lymphoma or multiple myeloma (types of blood cancer);
children from 1 year of age who have lymphoma or solid tumours.

Plerixafor Accord is a ‘generic medicine’. This means that Plerixafor Accord contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU. The reference medicine for Plerixafor Accord is Mozobil. For more information on generic medicines, see the question-and-answer document here.

Plerixafor Accord contains the active substance plerixafor.

: Plerixafor Accord is given as an injection under the skin. It can only be obtained with a prescription and treatment should only be started and supervised by a doctor who has experience in treating cancer or blood disorders. After the patient has been given Plerixafor Accord, their stem cells are extracted from the blood and stored before transplantation. Because of this, treatment should be carried out in collaboration with a specialised centre that has experience with this type of procedure and can monitor the stem cells.
Plerixafor Accord is used together with G-CSF. G-CSF is used on its own for 4 days before Plerixafor Accord is started. Plerixafor Accord is given 6 to 11 hours before the patient’s blood is taken and the stem cells are extracted. It can be used for up to 7 consecutive days. The dose depends on the bodyweight of the patient.
For more information about using Plerixafor Accord, see the package leaflet or contact your doctor or pharmacist.

: Plerixafor Accord is used to mobilise the stem cells from the bone marrow so they can be released into the blood. The active substance in Plerixafor Accord, plerixafor, works by blocking the activity of a protein called ‘CXCR4 chemokine receptor’. This protein normally helps to keep stem cells within the bone marrow. By blocking its activity, Plerixafor Accord allows the stem cells to be released into the blood, so that they can be collected.

: Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Mozobil, and do not need to be repeated for Plerixafor Accord.
As for every medicine, the company provided studies on the quality of Plerixafor Accord. There was no need for ‘bioequivalence’ studies to investigate whether Plerixafor Accord is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. This is because the composition of Plerixafor Accord is very similar to the reference medicine and when given by injection under the skin, the active substance in both products is expected to be absorbed in the same way.

: Because Plerixafor Accord is a generic medicine, its benefits and risks are taken as being the same as the reference medicine’s.

: The European Medicines Agency concluded that, in accordance with EU requirements, Plerixafor Accord has been shown to be comparable to Mozobil. Therefore, the Agency’s view was that, as for Mozobil, the benefits of Plerixafor Accord outweigh the identified risks and it can be authorised for use in the EU.

: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Plerixafor Accord have been included in the summary of product characteristics and the package leaflet.
As for all medicines, data on the use of Plerixafor Accord are continuously monitored. Suspected side effects reported with Plerixafor Accord are carefully evaluated and any necessary action taken to protect patients.

: Plerixafor Accord received a marketing authorisation valid throughout the EU on 16 December 2022.
Further information on Plerixafor Accord can be found on the Agency’s website: ema.europa.eu/medicines/human/EPAR/plerixafor-accord. Information on the reference medicine can also be found on the Agency’s website.
This overview was last updated in 12-2022.

List item

Plerixafor Accord : EPAR - Medicine overview (PDF/167.1 KB)

First published: 06/02/2023
EMA/851603/2022
- Bulgarian
  (PDF/192.75 KB)
- Croatian
  (PDF/185.59 KB)
- Czech
  (PDF/189.09 KB)
- Danish
  (PDF/166.79 KB)
- Dutch
  (PDF/168.73 KB)
- Estonian
  (PDF/156.08 KB)
- Finnish
  (PDF/165.95 KB)
- French
  (PDF/169.77 KB)
- German
  (PDF/171.53 KB)
- Greek
  (PDF/192.65 KB)
- Hungarian
  (PDF/190.64 KB)
- Italian
  (PDF/166.42 KB)
- Latvian
  (PDF/198.22 KB)
- Lithuanian
  (PDF/188.67 KB)
- Maltese
  (PDF/190.39 KB)
- Polish
  (PDF/194.82 KB)
- Portuguese
  (PDF/169.04 KB)
- Romanian
  (PDF/188.81 KB)
- Slovak
  (PDF/188.95 KB)
- Slovenian
  (PDF/187.22 KB)
- Spanish
  (PDF/168.36 KB)
- Swedish
  (PDF/165.95 KB)
List item

Plerixafor Accord : EPAR - Risk-management-plan summary (PDF/102.56 KB)

First published: 06/02/2023

This EPAR was last updated on 06/02/2023

Authorisation details

Product details
Name	Plerixafor Accord
Agency product number	EMEA/H/C/005943
Active substance	Plerixafor
International non-proprietary name (INN) or common name	plerixafor
Therapeutic area (MeSH)	Multiple Myeloma Hematopoietic Stem Cell Transplantation
Anatomical therapeutic chemical (ATC) code	L03AX16
Additional monitoring	This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.
Generic	This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder	Accord Healthcare S.L.U.
Date of issue of marketing authorisation valid throughout the European Union	16/12/2022
Contact address	Accord Healthcare S.L.U. Edificio Este Planta 6a World Trade Center Moll De Barcelona S/n 08039 Barcelona SPAIN

Product information

16/12/2022 Plerixafor Accord - EMEA/H/C/005943 -

List item

Plerixafor Accord : EPAR - Product Information (PDF/557.91 KB)

First published: 06/02/2023
- Bulgarian
  (PDF/668.29 KB)
- Croatian
  (PDF/509.44 KB)
- Czech
  (PDF/511.52 KB)
- Danish
  (PDF/568.26 KB)
- Dutch
  (PDF/411.08 KB)
- Estonian
  (PDF/413.23 KB)
- Finnish
  (PDF/407.81 KB)
- French
  (PDF/650.01 KB)
- German
  (PDF/491.51 KB)
- Greek
  (PDF/738.34 KB)
- Hungarian
  (PDF/542.27 KB)
- Icelandic
  (PDF/415.59 KB)
- Italian
  (PDF/415.62 KB)
- Latvian
  (PDF/509.16 KB)
- Lithuanian
  (PDF/549.56 KB)
- Maltese
  (PDF/548.42 KB)
- Norwegian
  (PDF/445.62 KB)
- Polish
  (PDF/522.23 KB)
- Portuguese
  (PDF/416.69 KB)
- Romanian
  (PDF/555.71 KB)
- Slovak
  (PDF/514.1 KB)
- Slovenian
  (PDF/494.4 KB)
- Spanish
  (PDF/407.33 KB)
- Swedish
  (PDF/512.92 KB)

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

Product information documents contain:

summary of product characteristics (annex I);
manufacturing authorisation holder responsible for batch release (annex IIA);
conditions of the marketing authorisation (annex IIB);
labelling (annex IIIA);
package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

List item

Plerixafor Accord : EPAR - All authorised presentations (PDF/83.57 KB)

First published: 06/02/2023
- Bulgarian
  (PDF/90.95 KB)
- Croatian
  (PDF/86.06 KB)
- Czech
  (PDF/100.82 KB)
- Danish
  (PDF/98.1 KB)
- Dutch
  (PDF/83.28 KB)
- Estonian
  (PDF/82.99 KB)
- Finnish
  (PDF/89.12 KB)
- French
  (PDF/93.76 KB)
- German
  (PDF/86.34 KB)
- Greek
  (PDF/88.33 KB)
- Hungarian
  (PDF/86.91 KB)
- Icelandic
  (PDF/89.59 KB)
- Italian
  (PDF/87.32 KB)
- Latvian
  (PDF/96.39 KB)
- Lithuanian
  (PDF/93.01 KB)
- Maltese
  (PDF/92.6 KB)
- Norwegian
  (PDF/86.72 KB)
- Polish
  (PDF/88.5 KB)
- Portuguese
  (PDF/85.42 KB)
- Romanian
  (PDF/94.15 KB)
- Slovak
  (PDF/96.29 KB)
- Slovenian
  (PDF/88.47 KB)
- Spanish
  (PDF/90.74 KB)
- Swedish
  (PDF/88.54 KB)

Pharmacotherapeutic group

Immunostimulants

Therapeutic indication

Adult patients

Plerixafor Accord is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4.2).

Paediatric patients (1 to less than 18 years)

Plerixafor Accord is indicated in combination with G-CSF to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:
- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with G-CSF (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or
- who previously failed to collect sufficient haematopoietic stem cells (see section 4.2).

Assessment history

Initial marketing-authorisation documents

News

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2022

14/10/2022

How useful was this page?

Add your rating

★ ★ ★ ★ ★

Plerixafor Accord

Table of contents

Overview